Individualized therapy for metastatic colorectal cancer

A. Silvestri, E. Pin, A. Huijbers, R. Pellicani, E. M. Parasido, M. Pierobon, E. Petricoin, L. Liotta*, C. Belluco

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

20 Scopus citations


Systemic therapeutic efficacy is central to determining the outcome of patients with metastatic colorectal cancer (CRC). In these patients, there is a critical need for predictive biomarkers to optimize efficacy whilst minimizing toxicity. The integration of a new generation of molecularly targeted drugs into the treatment of CRC, coupled with the development of sophisticated technologies for individual tumours as well as patient molecular profiling, underlines the potential for personalized medicine. In this review, we focus on the latest progress made within the genomic and proteomic fields, concerning predictive biomarkers for individualized therapy in metastatic CRC.

Original languageEnglish
Pages (from-to)1-24
Number of pages24
JournalJournal of Internal Medicine
Issue number1
StatePublished - Jul 2013
Externally publishedYes


  • Colorectal cancer
  • Genomic profiling
  • Individualized therapy
  • Predictive biomarkers
  • Proteomic profiling


Dive into the research topics of 'Individualized therapy for metastatic colorectal cancer'. Together they form a unique fingerprint.

Cite this